
|Articles|February 1, 2004
Emphasis on etanercept
Waikoloa, Hawaii - Phase III trials show etanercept (Enbrel, Amgen Inc. and Wyeth) has efficacy and safety for moderate to severe psoriasis.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
2
JAK Inhibitors Show Comparable Safety to TNF Antagonists
3
Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC
4
Balancing Pathophysiology and Patient Lifestyle in Acne Management: Part 1
5


















